Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system

Each ICI has distinctive features of pharmacovigilance signals. It is essential to acknowledge the AEs associated with the relevant system when clinicians administer ICIs.

Authors

Wenjun Liang (ORCID: https://orcid.org/0000-0002-6341-9277)
Jintao Chen
Xiaohua Wang (ORCID: https://orcid.org/0000-0001-9122-1535)
Xiaowei Yu (ORCID: https://orcid.org/0000-0001-8313-2559)
Ruichen Gao (ORCID: https://orcid.org/0000-0002-5652-2225)
Mingxia Yang (ORCID: https://orcid.org/0000-0001-5679-9323)

Institutions

Second Affiliated Hospital of Nanjing Medical University (CN)
Nanjing Medical University (CN)

Publication Details

Journal: BMC Cancer
Published: 2025-02-07
DOI: https://doi.org/10.1186/s12885-025-13614-1
Citations: 5
Primary Topic: Lung Cancer Treatments and Mutations
Type: article
Field-Weighted Citation Impact: 7.59

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system

Authors

Institutions

Publication Details

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system

Abstract

Ask Laika to Summarize, Analyze, and Connect papers live on the map.